Cameco vs. Centrus vs. BWX Technologies: Ranking the 3 Nuclear Stocks That Get Paid Before a Reactor Is Built.

BWX Technologies is presented as the safest nuclear-sector turnaround play, with projected 2025–2028 revenue and EPS CAGRs of 13% and 16%, respectively, and a 25x forward P/E. Cameco is projected to grow revenue 8% and EPS 39% annually, at 37x forward earnings; Centrus is projected to grow revenue 2% while EPS declines 11%, at 28x. Over the past 12 months, shares fell 8% for Cameco, 7% for BWX and 72% for Centrus; the article cites rising interest rates as a near-term risk to all three.

Analysis

The key disconnect is between nuclear demand narratives and funded, near-term orders. Data-center power needs do not automatically translate into reactor starts: utility procurement, licensing, grid interconnection and financing can defer equipment revenue for years. That favors businesses tied to funded defense programs and contracted work over names whose upside depends on a future fuel-market tightness or reactor deployment.

BWX Technologies (BWXT) looks the cleaner relative exposure, but defense diversification reduces earnings cyclicality—not valuation or execution risk. Watch backlog conversion, program margins and any evidence that new commercial or microreactor activity is consuming capacity without attractive returns. Cameco (CCO) has a different payoff: long-term contracting dampens spot-price torque, while Westinghouse could add services exposure if project awards turn into recurring cash flow. That optionality is not yet equivalent to realized earnings. Centrus (LEU) is the highest-variance case: domestic enrichment and HALEU capacity could become strategically valuable, but the investment case hinges on funded customer commitments, ramp yields and capital requirements, not policy rhetoric alone.

Over the next 1–3 months, rates and earnings guidance can dominate nuclear fundamentals; over 6–18 months, contract awards, production milestones and government procurement are the more meaningful catalysts. The contrarian risk to the article’s BWXT preference is that a lower relative multiple and forecast growth do not prove undervaluation when business mix, program risk and forecast quality differ. Conversely, the market may underprice fuel-cycle security if non-Russian supply remains constrained. Verify order funding, backlog quality, capex and production progress before sizing.

Key Decisions for Investors

• Relative-value idea: consider a modest long BWXT / short CCO position, sized to reduce broad-market and energy-factor exposure rather than assuming equal share counts hedge. Enter in tranches around earnings or on relative weakness; the thesis is better near-term visibility at BWXT versus CCO’s greater sensitivity to uranium pricing and project timing.
• Falsify the pair if BWXT backlog conversion or segment margins weaken, or if CCO reports material Westinghouse earnings contribution or stronger realized uranium pricing that lifts guidance. Reassess on each company’s next results; do not treat the supplied forward multiples as directly comparable measures of cheapness.
• Keep LEU on a catalyst watchlist rather than treating the share-price decline as a standalone entry signal. Upgrade only with evidence of funded offtake, government support translating into cash receipts, and credible domestic ramp/yield progress; check capex and funding needs first.
• Near-term risk control: rising real yields can compress valuations across all three despite operational progress. Reduce gross exposure if rates rise sharply alongside deteriorating equity performance; the structural nuclear thesis does not protect against multiple contraction.